Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Understanding SLE-Associated Skin Injury May Open the Door to Therapies

  |  

The authors ended their review article by describing several therapeutic targets that have the potential to control skin injury in SLE: TNF receptor superfamily member 1a, tyrosine-protein kinase SYK, calcium/calmodulin-dependent protein kinase type IV and nuclear factor of activated T cells.

Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

ADVERTISEMENT
SCROLL TO CONTINUE

Reference

  1. Deng GM, Tsokos GC. Pathogenesis and targeted treatment of skin injury in SLE. Nat Rev Rheumatol. 2015 Aug 4. doi: 10.1038/nrrheum.2015.106. [Epub ahead of print]

Related Articles

    Protein Phosphatase 2A and Regulatory T Cell Function Researched

    The serine-threonine protein phosphatase 2A (PP2A) enzyme is critical for regulatory T cells to function—without it, they don’t have the ability to suppress effector T cells and can’t protect against autoimmunity, according to new research published in Nature Immunology. Researchers found that conditional knockout mice—in which PP2A expression is knocked out only in regulatory T cells—developed…